Pfizer PFE Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Revenues: by Product | ||||||
| Abrysvo | $1.08B+4.7% | $1.03B+37.5% | $751M-9.3% | $828M+11.7% | $741M-1.9% | |
| Adcetris | $880M-3.1% | $908M-6.7% | $973M-5.2% | $1.03B-2.3% | $1.05B-3.6% | |
| All other Oncology | $1.33B-0.1% | $1.33B+1.4% | $1.31B+0.3% | $1.31B+2.6% | $1.28B+6.3% | |
| All other Primary Care | $2.9B+1.6% | $2.86B+0.1% | $2.85B-0.7% | $2.87B-0.8% | $2.9B-5.3% | |
| All other Specialty Care | $1.85B+5.3% | $1.76B+8.1% | $1.63B+5.4% | $1.54B-2.5% | $1.58B-1.7% | |
| Bosulif | $589M-3.6% | $611M-1.6% | $621M-1.7% | $632M-2.8% | $650M+0.9% | |
| Braftovi/Mektovi | $755M+5.3% | $717M+3.9% | $690M+4.4% | $661M+5.4% | $627M+3.3% | |
| Cibinqo | $302M+6.3% | $284M+5.6% | $269M+6.3% | $253M+9.5% | $231M+7.4% | |
| Comirnaty | $4.03B-7.6% | $4.37B-20.3% | $5.48B-4.7% | $5.75B+3.3% | $5.57B+3.9% | |
| Eliquis | $8.2B+3.1% | $7.96B+2.4% | $7.77B+5.4% | $7.38B+1.7% | $7.25B-1.6% | |
| Elrexfio | $324M+6.6% | $304M+5.9% | $287M+18.6% | $242M+35.2% | $179M+35.6% | |
| Enbrel (Outside the U.S. and Canada) | $625M-0.3% | $627M-0.6% | $631M-2.3% | $646M-3.7% | $671M-2.8% | |
| FSME-IMMUN/TicoVac | $337M+5.6% | $319M+4.2% | $306M+6.6% | $287M+3.2% | $278M-0.7% | |
| Genotropin | $444M-0.4% | $446M+1.1% | $441M+2.1% | $432M-2.9% | $445M-5.3% | |
| Ibrance | $4.15B+0.8% | $4.12B-1.3% | $4.18B-0.7% | $4.21B-1.9% | $4.29B-1.8% | |
| Inlyta | $918M-0.5% | $923M-0.8% | $930M-2.2% | $951M-0.9% | $960M-1.8% | |
| Lorbrena | $1.11B+8.1% | $1.02B+9.5% | $934M+7.1% | $872M+10.4% | $790M+7.9% | |
| Nurtec ODT/Vydura | $1.53B+7.4% | $1.42B+0.8% | $1.41B+5.6% | $1.34B+0.2% | $1.33B+5.5% | |
| Octagam | $452M+8.1% | $418M+2.7% | $407M-21.0% | $515M-1.3% | $522M+2.6% | |
| Oncology Biosimilars | $1.45B+11.1% | $1.3B+14.0% | $1.14B+2.7% | $1.11B+7.1% | $1.04B0.0% | |
| Orgovyx | $454M+7.8% | $421M+20.3% | $350M+18.6% | $295M— | —— | |
| Padcev | $2.11B+8.5% | $1.94B+3.4% | $1.88B+3.0% | $1.82B+8.8% | $1.67B+5.4% | |
| Pfizer CentreOne | $1.37B+1.2% | $1.35B+6.5% | $1.27B+4.9% | $1.21B+4.3% | $1.16B+1.3% | |
| Prevnar Family | $6.52B+0.5% | $6.49B+2.4% | $6.34B-1.0% | $6.4B+0.4% | $6.38B-0.5% | |
| Sulperazon (Outside the U.S. and Canada) | $688M+5.4% | $653M0.0% | $653M-0.3% | $655M+3.5% | $633M-0.5% | |
| Talzenna | $192M+5.5% | $182M+14.5% | $159M+7.4% | $148M+10.4% | $134M+14.5% | |
| Tivdak | $148M0.0% | $148M-3.3% | $153M+2.0% | $150M+9.5% | $137M+3.8% | |
| Tukysa | $483M+4.3% | $463M-2.1% | $473M-2.9% | $487M+2.3% | $476M-0.8% | |
| Vyndaqel family | $6.5B+1.8% | $6.38B+2.3% | $6.24B+2.4% | $6.09B+5.0% | $5.8B+6.4% | |
| Xeljanz | $1.14B+4.8% | $1.09B-2.3% | $1.11B-0.7% | $1.12B+1.7% | $1.1B-5.7% | |
| Xtandi | $2.18B-0.6% | $2.19B+1.2% | $2.17B+0.8% | $2.15B+3.4% | $2.08B+2.0% | |
| Zavicefta (Outside the U.S. and Canada) | $652M+2.4% | $637M+3.6% | $615M+1.0% | $609M+2.2% | $596M+1.7% | |
| Zithromax | $354M-11.5% | $400M-2.4% | $410M-2.4% | $420M-4.1% | $438M-8.8% | |
| Revenues: by Geography | ||||||
| International Developed Markets | $16.44B+1.5% | $16.19B-2.2% | $16.55B+1.7% | $16.27B+1.4% | $16.04B-0.1% | |
| International Emerging Markets | $9.44B+1.4% | $9.31B+2.8% | $9.06B+0.5% | $9.01B+1.6% | $8.88B0.0% | |
| U.S. | $37.44B+1.0% | $37.08B-0.3% | $37.18B-3.6% | $38.55B+2.7% | $37.55B-2.9% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Pfizer break its business down?
- Pfizer (PFE) reports revenues: by product across 36 parts — Abrysvo, Adcetris, All Other Hospital and Biosimilars, All other Oncology and All other Primary Care. Each is extracted from the segment footnotes and tracked over time.
- Where does Pfizer's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Pfizer's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
